BMS-332

BMS-332 is a dual DGKα/ζ lipid kinase inhibitor, with IC50s of 5 and 1 nM against DGKα and DGKζ, respectively. BMS-332 enhances the antigen-specific T cell response. BMS-332 reduces the viral load in the liver and spleen when combined with anti-PD-1 in chronic infection models. BMS-332 can be used for the study of T cell immune checkpoint strategy[1].

Product Specifications

CAS Number

[2407892-15-1]

UNSPSC

12352005

Target

DGK

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bms-332.html

Purity

99.05

Solubility

DMSO : 14.29 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CN(C1=CC=C(C#N)N=C1C(N2C[C@@H](C)N(C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)C[C@@H]2C)=C5)C5=O

Molecular Formula

C29H27F2N5O

Molecular Weight

499.55

References & Citations

[1]Wichroski M, et al. DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunity. Sci Transl Med. 2023;15 (719) :eadh1892.